The Androgenetic Alopecia market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Androgenetic Alopecia pipeline products will significantly revolutionize the Androgenetic Alopecia market dynamics.  

DelveInsight’s “Androgenetic Alopecia Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the Androgenetic Alopecia, historical and forecasted epidemiology as well as the Androgenetic Alopecia market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

The Androgenetic Alopecia market report covers emerging drugs, current treatment practices, market share of the individual therapies, and current & forecasted market size from 2020 to 2034. It also evaluates the current treatment practice/algorithm, market drivers & barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market. 

To Know in detail about the Androgenetic Alopecia market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Androgenetic Alopecia Market Insights

Some of the key facts of the Androgenetic Alopecia Market Report:  

• The Androgenetic Alopecia market size is anticipated to grow with a significant CAGR during the study period (2020-2034) 

• In July 2024, Eirion Therapeutics Inc. has announced the enrollment of the first participant in a Phase 1 clinical trial to assess the safety of their patented topical treatment, ET-02, for androgenic alopecia (age-related hair loss). This double-blind, placebo-controlled study aims to evaluate the safety of daily ET-02 application over a 28-day period. The trial plans to recruit around 24 participants at three research centers across the United States.

• In April 2024, Kintor Pharma has announced that its Phase II trial of GT20029 in China successfully met the primary endpoint, demonstrating significant results in treating male androgenetic alopecia (AGA). The trial assessed the efficacy and safety of Kintor Pharma’s first-in-class androgen receptor (AR) proteolysis-targeting chimera (PROTAC) compound, GT20029 tincture.

• According to the analysis, in 2023, the total number of prevalent cases of androgenetic alopecia across the 7MM was approximately 195 million, with the US accounting for nearly 83 million cases. These figures are expected to rise by 2034 due to sedentary lifestyles, which lead to hormonal changes that contribute to the development of androgenetic alopecia.

• In 2023, there were approximately 23 million diagnosed prevalent cases of androgenetic alopecia in males and 20 million in females in the US, indicating that the condition affects more men than women.

• In 2023, Germany had the highest prevalent population of androgenetic alopecia among the EU4 and the UK, with approximately 22 million cases, followed by the UK with around 17 million cases.

• Japan had approximately 28 million prevalent cases of androgenetic alopecia, and these cases are expected to rise during the forecast period due to the growing aging population in the country.

• As per study by Severi et al., the prevalence of vertex and full Androgenetic Alopecia increased with age from approximately 30% (age40–55 years) to 50% (age 65–69 years) 

• Key Androgenetic Alopecia Companies: Kintor Pharmaceutical, Cosmo Pharmaceuticals, Follicum AB, Cassiopea, Inc., and others 

• Key Androgenetic Alopecia Therapies: KX-826 (pyrilutamide), BREEZULA (clascoterone solution), FOL-005, Clascoterone solution 7.5%, and others 

• The Androgenetic Alopecia epidemiology based on gender analyzed that prevalence of Androgenetic Alopecia in males as compared to females; however, severity may vary in different age groups and race ethnicities

Androgenetic Alopecia Overview

Androgenetic Alopecia (AGA) or hair loss, is often referred to as ‘Male Pattern Baldness’ or’ Female Pattern Baldness’. Hair loss is a matter of enormous public interest and it significantly impacts the patient’s mental health. In-depth insights of pathophysiology and treatment landscape of various types of alopecia is imperative to exert a positive influence on the quality of life of the patients.

Get a Free sample for the Androgenetic Alopecia Market Report 

https://www.delveinsight.com/report-store/androgenetic-alopecia-market

Androgenetic Alopecia Market  

The dynamics of the Androgenetic Alopecia market are anticipated to change in the coming years owing to the expected launch of emerging therapies and others during the forecasted period 2020-2034.  

Androgenetic Alopecia Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Androgenetic Alopecia Epidemiology Segmentation:

The Androgenetic Alopecia market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:

• Total Prevalence of Androgenetic Alopecia

• Prevalent Cases of Androgenetic Alopecia by severity

• Gender-specific Prevalence of Androgenetic Alopecia

• Diagnosed Cases of Episodic and Chronic Androgenetic Alopecia

Download the report to understand which factors are driving Androgenetic Alopecia epidemiology trends @ Androgenetic Alopecia Epidemiological Insights

Androgenetic Alopecia Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Androgenetic Alopecia market or expected to get launched during the study period. The analysis covers Androgenetic Alopecia market uptake by drugs, patient uptake by therapies, and sales of each drug.  

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Androgenetic Alopecia Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyses recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Discover more about therapies set to grab major Androgenetic Alopecia market share @ Androgenetic Alopecia Medication

Androgenetic Alopecia Therapies and Key Companies

• KX-826 (pyrilutamide): Kintor Pharmaceutical

• BREEZULA (clascoterone solution): Cosmo Pharmaceuticals

• FOL-005: Follicum AB

• Clascoterone solution 7.5%: Cassiopea, Inc

Scope of the Androgenetic Alopecia Market Report

• Study Period: 2020–2034

• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

• Key Androgenetic Alopecia Companies: Kintor Pharmaceutical, Cosmo Pharmaceuticals, Follicum AB, Cassiopea, Inc, and others

• Key Androgenetic Alopecia Therapies: KX-826 (pyrilutamide), BREEZULA (clascoterone solution), FOL-005, Clascoterone solution 7.5%, and others

• Androgenetic Alopecia Therapeutic Assessment: Androgenetic Alopecia current marketed and Androgenetic Alopecia emerging therapies

• Androgenetic Alopecia Market Dynamics: Androgenetic Alopecia market drivers and Androgenetic Alopecia market barriers 

• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies

• Androgenetic Alopecia Unmet Needs, KOL’s views, Analyst’s views, Androgenetic Alopecia Market Access and Reimbursement  

To know more about Androgenetic Alopecia treatment, visit @ Androgenetic Alopecia Treatment Landscape

Table of Contents 

1. Androgenetic Alopecia Market Report Introduction

2. Executive Summary for Androgenetic Alopecia

3. SWOT analysis of Androgenetic Alopecia

4. Androgenetic Alopecia Patient Share (%) Overview at a Glance

5. Androgenetic Alopecia Market Overview at a Glance

6. Androgenetic Alopecia Disease Background and Overview

7. Androgenetic Alopecia Epidemiology and Patient Population

8. Country-Specific Patient Population of Androgenetic Alopecia 

9. Androgenetic Alopecia Current Treatment and Medical Practices

10. Androgenetic Alopecia Unmet Needs

11. Androgenetic Alopecia Emerging Therapies

12. Androgenetic Alopecia Market Outlook

13. Country-Wise Androgenetic Alopecia Market Analysis (2020–2034)

14. Androgenetic Alopecia Market Access and Reimbursement of Therapies

15. Androgenetic Alopecia Market Drivers

16. Androgenetic Alopecia Market Barriers

17.  Androgenetic Alopecia Appendix

18. Androgenetic Alopecia Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight 

DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/